Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Exp Clin Cancer Res
Main Authors: Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2016
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/
https://ncbi.nlm.nih.gov/pubmed/27604186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares